32293-43-9

Usage

Uses

Used in Pharmaceutical Research:
N-benzy-2-(4-(benzyloxy)phenyl)ethanamine is used as a research chemical for studying its potential applications in the treatment of psychiatric and neurological disorders. Its pharmacological and toxicological properties have been investigated, and it is considered to have potential therapeutic applications, particularly as a treatment for depression and other mood disorders.
Used in Controlled Substances Regulation:
Due to its psychoactive effects and potential for abuse, N-benzy-2-(4-(benzyloxy)phenyl)ethanamine is a controlled substance in many countries. This classification helps regulate its distribution and use, ensuring that it is only available for legitimate research and medical purposes.

InChI:InChI=1/C22H23NO.ClH/c1-3-7-20(8-4-1)17-23-16-15-19-11-13-22(14-12-19)24-18-21-9-5-2-6-10-21;/h1-14,23H,15-18H2;1H

Upstream product

• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 51-67-2 tyrosamine 
• 182921-01-3 N-(tert-butoxycarbonyl)-2-[4-(benzyloxy)phenyl]ethylamine 
• 788824-90-8 N-t-butoxycarbonyl-N-benzyl-O-benzyltyramine 

Relevant academic research and scientific papers

Trace amine-associated receptor agonists: Synthesis and evaluation of thyronamines and related analogues

We have previously shown that several thyronamines, decarboxylated and deiodinated metabolites of the thyroid hormone, potently activate an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale [Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S.; Lin, E. T.; Hatton, D.; Zucchi, R.; Grandy, D. K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10 (6), 638-642]. Herein, we report the synthesis of these thyronamines. Additionally, a large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction. Several derivatives were found to potently activate both rTAAR1 and mTAAR1 in vitro (compounds 77, 85, 91, and 92). When administered to mice at a 50 mg/kg dose, these derivatives all induced significant hypothermia within 60 min and exhibited a hypothermic induction profile analogous to 3-iodothyronamine (1, T1AM) except 91, which proved to be more efficacious. On the basis of this result, a dose-dependent profile for 91 was generated and an ED50 of 30 μmol/kg was calculated. Compound 91 proved to be more potent than T1AM for TAAR1 activation and exhibits increased potency and efficacy for hypothermia induction. These data further strengthen the pharmacological correlation linking TAAR1 activation by thyronamines and hypothermia induction in mice.